1179O - The European Thoracic Oncology platform Lungscape Project: a way to bridge non-small cell lung cancer molecular characteristics and clinical data

Date 30 September 2012
Event ESMO Congress 2012
Session NSCLC, metastatic I
Topics Non-Small-Cell Lung Cancer, Metastatic
Pathology/Molecular Biology
Presenter Solange Peters
Authors S. Peters1, O. Dafni2, L. Bubendorf3, P. Meldgaard4, K.J. O'Byrne5, A. Wrona6, W. Weder7, M. Canela8, S. Malatesta9, J.F. Vansteenkiste10, A.C. Dingemans11, M.C. Nicolson12, S. Savic13, P. Baas14, R. Peck15, S. Lu16, E.F. Smit17, E. Jantus-Lewintre18, R. Rosell19, R.A. Stahel20
  • 1Oncology, Centre Hospitalier Universitaire Vaudois - CHUV, 1011 - Lausanne/CH
  • 2Nursing - Laboratory Of Biostatistics, University of Athens, GR-11527 - Athens/GR
  • 3Division Of Cytology, Institute For Pathology, University Hospital Basel, 4031 - Basel/CH
  • 4Aarhus University Hospital, DK-8000 - Aarhus C/DK
  • 5Oncology, St James's Hospital, Dublin/IE
  • 6Oncology And Radiotherapy, Medical University of Gdansk, 211 - Gdansk/PL
  • 7Thoraxchirurgie, Univesitätspital Zurich, 8091 - Zürich/CH
  • 8Surgery, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 9Anatomia Patologica, Ospedale Clinicizzato, Chieti/IT
  • 10Respiratory Oncology Unit (pulmonology), University Hospital Gasthuisberg, BE-3000 - Leuven/BE
  • 11Pulmonology, Maastricht University Medical Center (MUMC), NL-6202 AZ - Maastricht/NL
  • 12Medical Oncology, Aberdeen Royal Infirmary, GB-AB25 2ZN - Aberdeen/UK
  • 13Pathology, Institute Of Pathology, University Hospital Basel, Basel/CH
  • 14The Netherlands Cancer Institute, Amsterdam/NL
  • 15-, University Hospital South Manchester and The Christie NHS Foundation Trust, Manchester/UK
  • 16Shanghai Lung Tumor Clinical Center, Shanghai Chest Hospital, 20030 - Shanghai/CN
  • 17Pulmonary, Vrije University Medical Centre (VUMC), NL-1081 HV - Amsterdam/NL
  • 18-, Fundacion para la Investigacion del Hospital General Universitario de Valencia, Valencia/ES
  • 19Medical Oncology Service, Catalan Institute of Oncology ICO Badalona Hospital Germans Trias i Pujol, Medical Oncology, 08916 - Badalona/ES
  • 20Clinic Of Oncology, Universitätsspital Zürich, 8091 - Zürich/CH

 

Abstract

Background

The Lungscape project aims at building a virtual biobank to facilitate an international high-quality analysis of large numbers of tumors for molecular alterations linked to clinical and biological characteristics captured in the iBiobank.

Methods

Retrospective radically resected stage I-III non-small cell lung cancer cases from 15 ETOP centers, with mandatory comprehensive clinical annotations including at least 2 years of FU have been reviewed and captured.

Results

This first set of 1614 cases was enriched in adenocarcinoma (61.8%), with 28.8% of squamous and 4.9% of large cell histologies. Median age is 65 yrs, 37.6% are women, and respectively 13.9%, 33.5% and 49.6% are never, current and former smokers. Stage distribution is: IA 23.7%, IB 25.8%, IIA 16.4%, IIB 11.6%, IIIA 20.8%, IIIB 1.7%. At last FU, 52.8% of patients were still alive, with a median FU of 5.3 yrs.

PFS No. of patients 5 years (95% C.I.) Median (mos) (95% C.I.)
TOTAL 1614 46 (43.3, 48.6) 49.0 ( 43.9, 55.2)
Stage Ia 382 64.5 (59.1, 60.5) NR
Ib 417 55.4 (50.3, 60.5) 78.0
IIa 264 44.8 (38.4, 51.3) 46.9
IIb 187 39.2 (31.6, 46.8) 33.7
IIIa 335 20.0 (15.2, 24.8) 17.5
IIIb 28 11.9 (0.0, 25.3) 10.1
OS 1614 52.0 (49.3, 54.7) 64.2 (57.3, 76.9)
Stage Ia 382 70.0 (64.9, 75.2) NR
Ib 417 60.6 (55.5, 65.7) NR
IIa 264 50.5 (43.8, 57.1) 62.2
IIb 187 43.7 (36.0, 51.4) 43.3
IIIa 335 29.3 (23.9, 34.7) 29.0
IIIb 28 10.3 (0.0, 27.1) 20.2

Conclusion

This is the first large-scale series based on 7th TNM classification reporting on OS and PFS in the context of European standards of care. These data confirm the discriminative capacity of the 7th TNM with a potentially somewhat superior outcome. Histologies other than adenocarcinoma are currently actively being captured. Complete data including PFS and TTP - never reported before - as well as OS based on the expected 2400 patients correlated to stage, gender, smoking status, histology and age will be provided. This complete clinical dataset will be invaluable to investigate the impact of molecular characteristics on outcome. It will allow building future hypothesis for prospective evaluation of new treatment strategies and help in the development of a molecularly refined TNM.

Disclosure

All authors have declared no conflicts of interest.